Candin for the Treatment of Common Warts

Inclusion Criteria:

• At least 3, but not more than 20 common warts (Verruca vulgaris)

• Willing to agree to use adequate contraception methods during the study

Exclusion Criteria:

• Systemic or localized diseases, conditions, or medications that could interfere withthe assessment of safety or efficacy or that compromise immune function

• Candin delayed type hypersensitivity reaction test wheal sized < 5 mm or > 25 mm atthe Baseline Visit

• History of keloid formation

• Prior treatment of common warts with liquid nitrogen, carbon dioxide,electrodesiccation, laser, surgery, salicylic acid, etc., that, in theInvestigator's opinion, does not exhibit complete healing from the treatment

• Treatment with immunotherapy (e.g., diphenylcyclopropenone [DPCP],dinitrochlorobenzene [DNCB], or other), imiquimod, 5-fluorouracil, bleomycin, orpodophyllin within 12 weeks of the Baseline Visit or during the study

• Prior treatment with Candida albicans within 12 weeks of the Baseline Visit orduring the study

• Systemic treatment with an immunosuppressive drug during the study or in the 6months or 5 half lives prior to the Baseline Visit or during the study (e.g.,azathioprine, 6 mercaptopurine, methotrexate, infliximab, adalimumab, etanercept,systemic steroids [topical or inhaled steroids are acceptable]).

• Use of cantharidin or an investigational agent or device within the 30 days prior tothe Baseline Visit or during the study